Project

A randomised, double-blind, placebo-controlled, phase I/II trial of RNActive®-derived Cancer Vaccine (CV9104) in asymptomatic or minimally symptomatic patients with me-tastatic castratic-refractory prostate cancer , Protocol CV-9104-004

Automatically Closed · 2012 until 2022

Rothermundt Christian